, the dialkoxy derivative (7b) was found to have the highest affinity at A 1 subtype receptor, and its radioligand binding activity together with 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) was studied. Finally, the structure-activity relationship (SAR) studies on the titled compounds provide some new insights about steric hindrance and lipophilic requirements for anchoring to the adenosine receptors recognition site.
1,2)
In addition, coupling with other messenger systems, such as calcium and potassium channels (A 1 receptor) or phospholipase C (A 1 , A 2B and A 3 receptors) and D (A 3 receptor), has been described. [3] [4] [5] [6] The A 1 and A 2A receptors are high affinity receptors, while A 2B and A 3 are low affinity ARs. 7, 8) The naturally occurring xanthines such as caffeine and theophylline were the initial prototypic AR antagonists. 9, 10) The many attempts to improve their potency and selectivity have resulted in the preparation of a large number of xanthine derivatives, and much is known now in terms of their structure activity and structure selectivity relationships, as well as about their pharmacological activity. [11] [12] [13] However, most of these xanthine derivatives showed poor water solubility and a high metabolic rate (specially due to their interaction with cytochrome P450 family) which strongly limitate its drug ability profile.
The extensive research in this topic has also led to the discovery of different classes of non-xanthine AR antagonists, being most of them nitrogen-containing heterocyclic compounds. [14] [15] [16] [17] [18] [19] [20] [21] [22] Some of the early described tricyclic adenosine antagonists were identified from collections of compounds initially designed as ligands of the benzodiazepine receptors. [14] [15] [16] [17] [18] Several elegant examples of the pharmacomodulation of these prototypes have allowed the development of new selective adenosine antagonists. Within the huge number of tricyclic heteroaromatic systems tested as adenosine antagonists (Fig. 1) those containing a 1,2,4-triazoloquinoxaline scaffold have been extensively explored, showing to be an extremely versatile motif during the identification of new valuable and selective AR ligands. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] In our previous papers, [34] [35] [36] we have described the synthetic methodology to obtain a new series of 2-alkoxy-[1,2,4]triazolo[1,5-a]quinazolin-5-ones and their derivatives 1-11, Chart 1. In this scenario, and as a part of our interest in the search for novel adenosine receptor antagonists, we herein report the pharmacological characterization of our compounds (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) at all adenosine receptor subtypes.
Results and Discussion
The binding results of compounds 2-11 are shown in Table 1 together with those of their parent compounds 1a-d. Moreover, the binding data of theophylline, 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) and some selective adenosine receptors, included as antagonist reference compounds in Table 2 , are also reported. [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] Examination of the binding results listed in Table 1 indicated that, the data obtained confirmed the structural modifications carried out on the 5-position of the tricyclic system 1 produces a remarkable modification of the adenosine receptorial profile in terms of affinity and/or selectivity.
The AR binding affinities of the parent compounds 1a-d indicate that, these compounds are almost selective at A 1 AR with K i values of 2.4-6.8 mM, and showed slight affinity at A 2A subtype. The modifications carried out on the parent structures 1a-d have different effects on A 1 , A 2A and A 2B affinities. For example, alkylation of lactam moiety in the parent compound 1b furnished N-alkylated products 2a-c, that were also tested in binding experiments, in particular affinity to A 1 and A 2A subtypes with respect to 1b. In addition, variation in the substituted alkyl groups have demonstrated remarkable binding affinities at A 1 , A 2A , A 2B receptors, such as compound 2b was displayed a significant K i value of 1.1 mM at A 1 in regard to the parent 1b (2.4 mM). Furthermore, 2b was found to possess the highest affinity at A 2B (IC 50 ϭ2.3 mM), although its parent 1b does not emerge to exhibit effect in the A 2B binding affinity. The reduction products 3a-c of 1a, b, d showed remarkable attenuated binding affinity at A 1 , where 3a gave K i value of 6 mM with respect to 2.4 mM for 1b, despite these compounds possess enhanced lipophilicity comparable to that parent compounds 1a, b, d.
Thionation of 1a, c, d into 4a-c was accomplished with significantly different changes in the terms of affinity. In particular, 4a showed good A 1 potency of 4.4 mM with respect to the parent 1d (6.8 mM), whereas slightly decrease in the affinity was noted in case of 4c (5 mM) in regard to 1a (4.25 mM). These results could suggest that, lactam or thiolactam moieties in 1 and 4 did not play an important role for anchoring their parent compounds to the ARs, but have been used also as suitable precursors for elaborating more derivatives with high affinity terms. Consequently, the thioether derivatives 5a, b of compound 4b showed remarkable significant improvement the affinity towards A 1 , A 2B and A 3 subtypes. In particular, 5a was found to exhibit high affinity at A 1 (3.4 mM) with respect to 4b (Ͼ10 mM), and was advantageous for A 2B receptor-ligand interaction comparable to that of the parent 4b.
It has been demonstrated that introduction of electron withdrawing atoms or groups in triazoloquinazoline rings enhances strongly the binding affinity towards benzodiazepine and adenosine A 1 , A 2A receptors. 48, 49) Within our work, conversion of the lactam moiety in 1a, b, d into an imidoyl chloride function 6a-c has not influenced positively effects on the affinity profiles towards A 1 and A 2A . However, compounds 6a, c have emerged almost the same behavior in the terms of affinity at A 1 subtype (4, 6.8 mM) with their parent compounds 1a, d (4.25, 6.8 mM), whereas 6b was less potent than 1b. Furthermore, the presence of chloride functional group in 5-position of 6a-c does seem to offer slightly advantageous for A 2B and A 3 affinity. Nevertheless, the significantly A 1 AR affinity of triazoloquinzolines 6a-c bearing at the 5-position a chlorine atom indicates that, not only chloro lipophilic factor, but also the steric effect are important for anchoring the ARs recognition. Thus, replacement of the chlorine atom in 6a-c by different nucleophiles provided access to a variety of derivatives with a variable affinity towards adenosine receptor subtypes. For instance, the dialkoxy triazoloquinazolines 7a-c derivatives represent the most populated set of compounds obtained during this study, particularly 7b was found to display the highest affinity at A 1 receptor with a K i value of 0.068 mM in regard to the parent 6a (4 mM). Moreover, the best results in terms of affinity which has shown in 7a, b may be attributed to the presence of steric hindrance of alkoxy groups in 5-position. This indicates, such functionalization in 7a, b is favorable for the interaction with the A 1 adenosine receptor subtype (K i ϭ0.154 and 0.068 mM for 7a and 7b respectively). However, it is worth noting that the dialkoxy triazoloquinazoline 7b possesses the highest A 1 AR affinity among the herein reported compounds. Furthermore, it has been found that, 7b was proved to be a potent A 1 AR antagonist (IC 50 ϭ108 nM) in regard to the DPCPX. On the contrary, a dramatic drop of affinity was observed by hydrazines 8a, b and carbazides 9a, b; this behavior confirmed that such functionalization hindered the interaction with adenosine receptors due to decrease of the lipophilicity. Finally, the transformation of the tricyclic systems 6b, c into tetracyclcic systems 10a, b and 11a, b does not offer advantageous in the affinity terms at A 1 . However, compound 10b showed better potency (1.75 mM) than its parent 6c (6.8 mM). As well as, these results indicate that, the presence of fused ring is not well tolerated for anchoring to the ARs recognition site.
In conculsion, structure modifications on the lead compound 1 have afforded derivatives with a variety of ARs affinity terms. A comparison study was reported between the tested 1,2,4-triazolo[1,5-a]quinazoline derivatives and some adenosine antagonists references using xanthine and nonxanthine compounds. Most of the tested compounds have been disclosed as A 1 AR antagonists with different K i values. Among of them, compounds 7a, b were displayed potent A 1 antagonist activity with respect to DPCPX, while compound 2b was nonselective and being potent antagonist at A 1 and A 2B subtypes with regard to the DPCPX and MRS-1754.
Moreover, the structure-activity relationship (SAR) study of compounds 1-11 gave us some useful insights about the characteristics requirements for the optimal anchoring of the targeted compounds to the ARs recognition site, which may be taken into consideration in the design of new ARs antagonists.
Experimental
Radioligand Binding Assay The cells were grown adherently and maintained in Dulbecco's modified Eagle's medium with nutrient mixture F12 without nucleosides at 37°C in 5% CO 2 95% air. The standard assay medium was prepared by FBS (fetal bovine serum), P/S (Penicillin/Streptomycin) and Geneticin. The cells were washed with phosphate-buffered saline and scrapped off flasks in ice cold hypotonic buffer (50 mM Tris-HCl, 100 mM ethylenediaminetetraacetic acid (EDTA), water, pH 7.4 at 4°C). The cell suspension was homogenized with a Polytron and the homogenate was centrifuged for 30 min at 18000 rpm. The membrane pellet was resuspended in 50 mM Tris-HCl buffer at pH 7.4 for A 1 50, 51) were utilized in radioligand binding assay to membranes prepared from Chinese hamster ovary (CHO) cells expressing the appropriate adenosine receptors on their surfaces. 52) Adenosine-deaminase (ADA) was present during the preparation of the membranes, in a preincubation of 30 min at 37°C, and during the incubation with the radioligands. All nonradioactive compounds were initially dissolved in dimethyl sulfoxide (DMSO) and diluted with buffer to the final concentration, where the amount of DMSO never exceeded 2%. Bound and free radioactivity were separated by rapid filtration through Whatman GF/B glass-fiber filters which were washed three times with ice cold buffer. The filter bound radioactivity was counted in a Beckman LS-1800 spectrometer (efficiency 55%). Inhibitory binding constant, K i , and IC 50 were calculated according to the Cheng-Prusoff equation (K i ϭIC 50 /(1ϩ[*DPCPX]/K d ). Where [*DPCPX] is the concentration of the radioligands (1 nM) and dissociation constant (K d ) of radioligands for *DPCPX, and *ZM are 1 and 2 nM respectively. Binding experiments at human A 2B and A 3 receptors were performed on crude membranes obtained from CHO cells and the procedure was carried out as described previously with minor modifications.
52) The cells were dissolved with 2 ml of tyrpsine and washed with phosphate-buffered saline. The cell suspension was centrifuged for (10 min, 12000 rpm, 40°C). The membrane pellet was resuspended in 5 ml cAMP puffer at 37°C. To the preparation medium was added RO-20-1724 (4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinon) as phosphodiesterase-inhibitor and NECA (5-(6-amino-9H-purin-9-yl)-N-ethyl-3,4-dihydroxytetrahydrofuran-2-carboxamide) as non selective adenosine agonist. IC 50 values for concentration-dependent inhibition of NECA-stimulated adenylyl cyclase caused by antagonists were calculated according to Cheng and Prusoff equation. The protein concentration was determined according to a Bio-Rad method. 53) The K i values for antagonists were then calculated with the Cheng and Prusoff equation. 54) 
